Tilray: Fourth Quarter Consensus Estimates

Tilray (TSX: TLRY) (NASDAQ: TLRY) will be reporting its fourth quarter financial results on July 28 before the market opens. Analysts have a consensus $17.77 12-month price target on the company, via a total of 20 analysts, with 2 analysts having strong buy ratings. 3 analysts meanwhile have buy ratings, 14 have hold ratings and a single analyst has a sell rating on the company. The street high comes from Roth Capital with a $25 price target, and the lowest target sits at $1.27 from GLJ Research.

10 analysts have revenue estimates for the fourth quarter. The mean revenue estimate between all 10 analysts is $146.19 million; this number has been revised upwards from $71.20 million at the start of the year. The highest revenue estimate is $175.4 million, while the lowest is $107.62 million.

Onto EBITDA estimates, there are currently 7 analysts who have fourth-quarter EBITDA estimates. The mean is currently $5.81 million, with this number being flat since the start of the year. The street high estimate currently sits at $11.7 million in EBITDA and the lowest is -$2.83 million.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

IAMGOLD Q3 Earnings: Market Responds With MASSIVE Price Lift

G Mining Q3 Earnings: Costs Down, Production Up

Endeavour Silver Q3 Earnings: On The Upswing

Recommended

Silver47 Hits 606 g/t Over 9.7 Metres Silver Equivalent In Final Assays From 2025 Drill Program At Red Mountain

Altamira Gold Encounters Second Porphyry Body, Hitting 3.5 g/t Gold Over 8.0 Metres

Related News

PayPal: Analysts Call For Earnings Per Share Of $0.86 For Q2 2022

PayPal Holdings (NASDAQ: PYPL) will be reporting its second quarter financial results today after market...

Tuesday, August 2, 2022, 02:23:00 PM

CareRx: Canaccord Raises Price Target To $6.50 Following Financing

Earlier this week, CareRx Corp (TSX: CRRX) closed their C$21.2 million bought deal. Notably, $6.25...

Friday, February 5, 2021, 11:45:00 AM

BMO Reiterates $21 Price Target On Osisko Gold Royalties

Last week, Osisko Gold Royalties (TSX: OR) announced their preliminary second quarter deliveries and gave...

Thursday, July 22, 2021, 01:48:00 PM

Cresco Labs: Stifel Slashes Price Target From $30 To $8 Following Poor Q4 Results

On March 23rd, Cresco Labs (CSE: CL) announced its fourth-quarter financial results, which disappointed many...

Friday, March 25, 2022, 03:39:00 PM

Sundial Growers: Canaccord Raises Price Target To US$0.65

On March 17th, Sundial Growers (NASDAQ: SNDL) reported their fourth quarter and year end financial...

Friday, March 19, 2021, 04:15:00 PM